Does Rallies show 13F holders for IMRX?

Yes. Rallies tracks hedge fund and 13F ownership data for IMRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IMRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.

IMRX (Immuneering Corporation Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMRX trades at $4.97 with a market cap of $315.08M and a P/E ratio of -3.91. IMRX moved +2.97% today. Year to date, IMRX is -24.05%; over the trailing twelve months it is +219.75%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IMRX stock?

Hedge funds tracked by Rallies that own IMRX include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immuneering Corporation Class A Common Stock.

IMRX Key Metrics

Key financial metrics for IMRX
Metric	Value
Price	$4.97
Market Cap	$315.08M
P/E Ratio	-3.91
EPS	$-1.27
Dividend Yield	0.00%
52-Week High	$10.08
52-Week Low	$1.10
Volume	8.69K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-56.02M
Gross Margin	0.00%

Top Hedge Funds Holding IMRX

Exoduspoint Capital holds 1.52M shares of IMRX, changed +5643.40% as of Sep 30, 2025.

Latest IMRX News

Phase 2a Pancreatic Cancer Trial Delivers 64% 12-Month OS, Shares Plunge 26.5% — Jan 8, 2026

Recent IMRX Insider Trades

Brakewood Harold Eugene bought 5.25K (~$24.99K) on Jan 16, 2026.
Schall Thomas J. bought 21.64K (~$101.04K) on Jan 15, 2026.
Hall Brett Matthew bought 2.30K (~$10.50K) on Jan 15, 2026.

IMRX Analyst Consensus

5 analysts cover IMRX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.

Common questions about IMRX

Who owns IMRX stock?: Hedge funds tracked by Rallies that own IMRX include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Immuneering Corporation Class A Common Stock.
Does Rallies show 13F holders for IMRX?: Yes. Rallies tracks hedge fund and 13F ownership data for IMRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IMRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.